Medicus Pharma highlighted positive Phase 2 SkinJect data in basal cell carcinoma and regulatory progress in Gorlin syndrome, while advancing Teverelix across prostate cancer, acute urinary retention, and endometriosis programs.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
Medicus Pharma will present new clinical, regulatory, and strategic updates across its oncology, urology, and women’s health pipeline during the BIO International Convention 2026 in San Diego. The presentation will highlight positive Phase 2 data for SkinJect® in basal cell carcinoma (BCC) and continued advancement of Teverelix®, a next-generation GnRH antagonist under development across multiple indications.
Chief Medical Officer Dr. Faisal Mehmud is scheduled to discuss recent milestones, including preparations for SkinJect’s regulatory pathway and progress in the company’s precision medicine-focused endometriosis program.
SkinJect Advances Along FDA Regulatory Pathway
SkinJect is an investigational lesion-directed therapy that delivers doxorubicin directly into skin cancer lesions through dissolvable microneedle arrays. The localized approach targets tumors directly while limiting systemic drug exposure.
The company recently reported positive results from the Phase 2 SKNJCT-003 trial in patients with nodular basal cell carcinoma. At 200 μg, SkinJect achieved 55% histological and 64% clinical clearance, with a clear dose-response supporting registrational development.
Medicus is preparing for an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss a potential registrational development strategy. The company is also pursuing regulatory incentives for SkinJect in Gorlin syndrome, a rare inherited disorder characterized by recurrent and multiple basal cell carcinomas that often develop early in life.
FDA review of Orphan Drug Designation and Rare Pediatric Disease Designation requests for Gorlin syndrome could provide regulatory incentives, including market exclusivity and expedited development opportunities if granted. Medicus believes SkinJect could become the first FDA-approved lesion-directed therapy developed specifically for patients with Gorlin syndrome, a population with significant unmet medical need.
Teverelix Expands Across Multiple Therapeutic Areas
Teverelix is a next-generation gonadotropin-releasing hormone (GnRH) antagonist under development for advanced prostate cancer, acute urinary retention relapse (AURr), and endometriosis.
In advanced prostate cancer, Medicus recently submitted a substantial modification application through the European Union Clinical Trials Information System (CTIS) to support a planned Phase 2b dose-optimization study. The broader program focuses on patients with elevated cardiovascular risk, a population where treatment options remain limited.
The company is also advancing Teverelix for prevention of recurrent acute urinary retention following successful catheter removal. Currently, no approved therapies specifically prevent recurrence in this setting.
In women’s health, Medicus recently launched the PRECISION-E2 Phase 2a study in women with moderate-to-severe endometriosis. Conducted in collaboration with the United Arab Emirates Genome Program, the study integrates genomic profiling with hormonal therapy to identify genetic markers associated with treatment response. The approach could help establish a precision medicine framework for future endometriosis management and patient selection.
Strategic Focus on Phase 2 Milestones
Medicus continues to prioritize Phase 2 clinical development as a key value-inflection stage across its pipeline. By generating robust clinical and regulatory datasets, the company aims to reduce development risk before pursuing strategic partnerships, regional licensing agreements, and commercialization collaborations.
Upcoming catalysts include FDA discussions for SkinJect, advancement of Teverelix clinical programs, and emerging genomic data from the PRECISION-E2 study. Together, these developments represent important milestones across the company’s oncology, urology, and women’s health portfolio.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.